HRAS Mutational Analysis
To identify point mutations in exons 2 and 3 of HRAS, a proto-oncogene that belongs to the family of Ras oncogenes, that is frequently mutated in bladder carcinomas, follicular thyroid carcinomas, and various sarcomas including malignant fibrous histiocytoma (MFH), leiomyosarcomas, rhabdomyosarcomas and dedifferentiated liposarcomas. Germline HRAS mutations are also identified in rare developmental disorder known as Costello syndrome. Assessment of theHRAS mutational status may identify patients likely to benefit from treatment byRAS inhibitors that are currently undergoing clinical trials.
This test is performed by PCR-based Sanger sequencing of DNA to examine the mutation status of exons 2 and 3 of HRAS.
This assay will detect mutations present in exons 2 and 3 of HRAS. The sensitivity of the Sanger sequencing assay is 20% of variant sequence in the background of wild-type sequence.
• 10 ug of purified DNA, sent on dry ice
• Four to six unstained recut slides of formalin-fixed, paraffin embedded tissue containing adequate amounts of tumor to be analyzed (See Sensitivity).
The area of tumor to be analyzed should be indicated by circling the area on the bottom side of the slide or in a separate H&E-stained guide section.
Please provide a copy of the corresponding pathology report.
Additional charges may apply for tissue extraction.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.